A remotely regulated living bionic heart patch is pictured. The engineered tissue is comprised of living cardiac cells, polymers, and a complex nanoelectronic system. This integrated electronic system provides enhanced capabilities, such as online sensing of heart contraction and pacing when needed. In addition, the electronics can control the release of growth factors and drugs for stem cell recruitment and to decrease inflammation after transplantation. [Tel Aviv University]

Scientists from Tel Aviv University think they found a way to help people on waiting lists for a heart transplant. The researchers reported in Nature Materials the development of a bionic heart patch that combines organic and engineered parts “Engineered Hybrid Cardiac Patches with Multifunctional Electronics for Online Monitoring and Regulation of Tissue Function“. The team says capabilities actually surpass those of human tissue alone because the patch contracts and expands like human heart tissue but regulates itself like a machine.

The invention is the brainchild of Tal Dvir, Ph.D., and doctoral student Ron Feiner of TAU’s Department of Biotechnology, Department of Materials Science and Engineering, and Center for Nanoscience and Nanotechnology.

“With this heart patch, we have integrated electronics and living tissue,” Dr. Dvir said. “It’s very science fiction, but it’s already here, and we expect it to move cardiac research forward in a big way. Until now, we could only engineer organic cardiac tissue, with mixed results. Now we have produced viable bionic tissue, which ensures that the heart tissue will function properly.”

Dr. Dvir’s Tissue Engineering and Regenerative Medicine Lab at TAU has been working on harnessing sophisticated nanotechnological tools to develop functional substitutes for tissue permanently damaged by heart attacks and cardiac disease. The new cyborg cardiac patch not only replaces organic tissue but also ensures its sound functioning through remote monitoring, according to the researcher.

“We first ensured that the cells would contract in the patch, which explains the need for organic material,” said Dr. Dvir. “But, just as importantly, we needed to verify what was happening in the patch and regulate its function. We also wanted to be able to release drugs from the patch directly onto the heart to improve its integration with the host body.”

For the new bionic patch, Dr. Dvir and his team engineered thick bionic tissue suitable for transplantation. The engineered tissue features electronics that sense tissue function and accordingly provide electrical stimulation. In addition, electroactive polymers are integrated with the electronics. Upon activation, these polymers are able to release medication, such as growth factors or small molecules on demand.

“Imagine that a patient is just sitting at home, not feeling well,” Dr. Dvir said. “His physician will be able to log onto his computer and this patient’s file in real time. He can view data sent remotely from sensors embedded in the engineered tissue and assess exactly how his patient is doing. He can intervene to properly pace the heart and activate drugs to regenerate tissue from afar. The longer-term goal is for the cardiac patch to be able to regulate its own welfare. In other words, if it senses inflammation, it will release an anti-inflammatory drug. If it senses a lack of oxygen, it will release molecules that recruit blood-vessel-forming cells to the heart.”

Dr. Dvir is currently examining how his proof of concept could apply to the brain and spinal cord to treat neurological conditions.

“This is a breakthrough, to be sure,” noted Dr. Dvir. “But I would not suggest binging on cheeseburgers or quitting sports just yet. The practical realization of the technology may take some time. Meanwhile, a healthy lifestyle is still the best way to keep your heart healthy.”

Previous articleThe Biopharmaceutical Challenge: Gyrolab Immunoassays Maximize Productivity in Bioprocess Development
Next articleOrexigen Re-Acquires U.S. Rights to Contrave from Takeda
Previous articleThe Biopharmaceutical Challenge: Gyrolab Immunoassays Maximize Productivity in Bioprocess Development
Next articleOrexigen Re-Acquires U.S. Rights to Contrave from Takeda